Company
United StatesPublic company, NASDAQ: AXGNAxoGen Corporation (NASDAQ: AXGN), Dayton, OH – FDA Inspections
Inspection records and compliance data for AxoGen Corporation in Dayton, Ohio. 5 FDA inspections on record, last inspected April 09, 2026. Publicly traded as NASDAQ: AXGN.
Company Profile
This profile covers AxoGen Corporation based in Dayton, Ohio, United States.
FDA Inspection History
- FDA inspections
- 5
- OAI
- 0
- VAI
- 0
- NAI
- 4
- Unclassified
- 1
- Form 483s
- 0
- Warning letters
- 0
First inspected March 14, 2013. Last inspected April 9, 2026.
FDA inspections (5)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| April 9, 2026 | Not classified | Biologics | 1315568 |
| September 22, 2022 | NAI | Biologics · Human Cellular, Tissue, and Gene Therapies | 1180500 |
| October 28, 2016 | NAI | Biologics · Human Cellular, Tissue, and Gene Therapies | 990232 |
| March 13, 2015 | NAI | Biologics · Human Cellular, Tissue, and Gene Therapies | 919999 |
| March 14, 2013 | NAI | Biologics · Human Cellular, Tissue, and Gene Therapies | 823344 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
AxoGen Corporation
Stock ticker
AXGN
Exchange
NASDAQ
Share price
$48.92
Market cap
$2.9B
Price as of
November 6, 2026
FEI Number
3012085771
Address
349 S Main St, Floor 4, Dayton, Ohio 45402, United States
Country
United States
ID: 66fee473-9012-4a34-be96-52430f5ca334